Malcolm A Leissring

List of Publications by Year
in descending order

62	5,485	126907	128289
papers	citations	33 h-index	60 g-index

66	66	66	5738
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Enhanced Proteolysis of Î²-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death. Neuron, 2003, 40, 1087-1093.	8.1	665
2	Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends in Neurosciences, 2000, 23, 222-229.	8.6	469
3	Capacitative Calcium Entry Deficits and Elevated Luminal Calcium Content in Mutant Presenilin-1 Knockin Mice. Journal of Cell Biology, 2000, 149, 793-798.	5.2	313
4	Proteolytic Degradation of Amyloid Â-Protein. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006379-a006379.	6.2	293
5	Accelerated Lipofuscinosis and Ubiquitination in Granulin Knockout Mice Suggest a Role for Progranulin in Successful Aging. American Journal of Pathology, 2010, 177, 311-324.	3.8	262
6	A physiologic signaling role for the Î³-secretase-derived intracellular fragment of APP. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4697-4702.	7.1	261
7	Partial Loss-of-Function Mutations in Insulin-Degrading Enzyme that Induce Diabetes also Impair Degradation of Amyloid Î²-Protein. American Journal of Pathology, 2004, 164, 1425-1434.	3.8	233
8	Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature, 2014, 511, 94-98.	27.8	207
9	Alzheimer's Presenilin-1 Mutation Potentiates Inositol 1,4,5-Trisphosphate-Mediated Calcium Signaling in Xenopus. Journal of Neurochemistry, 1999, 72, 1061.	3.9	162
10	Loss of Neprilysin Function Promotes Amyloid Plaque Formation and Causes Cerebral Amyloid Angiopathy. American Journal of Pathology, 2007, 171, 241-251.	3.8	157
11	Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochemical Journal, 2004, 383, 439-446.	3.7	152
12	Presenilin-2 Mutations Modulate Amplitude and Kinetics of Inositol 1,4,5-Trisphosphate-mediated Calcium Signals. Journal of Biological Chemistry, 1999, 274, 32535-32538.	3.4	126
13	Alzheimer's Presenilinâ€1 Mutation Potentiates Inositol 1,4,5â€Trisphosphateâ€Mediated Calcium Signaling in Xenopus. Journal of Neurochemistry, 1999, 72, 1061-1068.	3.9	121
14	Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral AÎ² assembly forms throughout life. Neurobiology of Disease, 2009, 36, 293-302.	4.4	117
15	Structure of Substrate-free Human Insulin-degrading Enzyme (IDE) and Biophysical Analysis of ATP-induced Conformational Switch of IDE. Journal of Biological Chemistry, 2007, 282, 25453-25463.	3.4	108
16	Kinetics of Amyloid Î²-Protein Degradation Determined by Novel Fluorescence- and Fluorescence Polarization-based Assays. Journal of Biological Chemistry, 2003, 278, 37314-37320.	3.4	106
17	Inclusion body myositis-like phenotype induced by transgenic overexpression of Î²APP in skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6334-6339.	7.1	103
18	Multiphoton-evoked color change of DsRed as an optical highlighter for cellular and subcellular labeling. Nature Biotechnology, 2001, 19, 645-649.	17.5	92

#	Article	IF	Citations
19	Designed Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of Insulin. PLoS ONE, 2010, 5, e10504.	2.5	91
20	Calsenilin reverses presenilin-mediated enhancement of calcium signaling. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8590-8593.	7.1	89
21	Decreased Catalytic Activity of the Insulin-degrading Enzyme in Chromosome 10-Linked Alzheimer Disease Families. Journal of Biological Chemistry, 2007, 282, 7825-7832.	3.4	89
22	Deletion of Insulin-Degrading Enzyme Elicits Antipodal, Age-Dependent Effects on Glucose and Insulin Tolerance. PLoS ONE, 2011, 6, e20818.	2.5	89
23	Aggregation and catabolism of disease-associated intra-AÎ² mutations: reduced proteolysis of AÎ²A21G by neprilysin. Neurobiology of Disease, 2008, 31, 442-450.	4.4	88
24	The AÎ²Cs of AÎ²-cleaving Proteases. Journal of Biological Chemistry, 2008, 283, 29645-29649.	3.4	79
25	Alternative Splicing of Human Insulin-Degrading Enzyme Yields a Novel Isoform with a Decreased Ability To Degrade Insulin and Amyloid Î²-Proteinâ€. Biochemistry, 2005, 44, 6513-6525.	2.5	78
26	Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. Molecular Neurodegeneration, 2009, 4, 4.	10.8	76
27	Regional Hypomyelination and Dysplasia in Transgenic Mice with Astrocyte-Directed Expression of Interferon-Î³. Journal of Molecular Neuroscience, 2000, 15, 45-60.	2.3	73
28	Small-Molecule Activators of Insulin-Degrading Enzyme Discovered through High-Throughput Compound Screening. PLoS ONE, 2009, 4, e5274.	2.5	63
29	Subcellular Mechanisms of Presenilin-Mediated Enhancement of Calcium Signaling. Neurobiology of Disease, 2001, 8, 469-478.	4.4	55
30	Molecular basis for the thiol sensitivity of insulin-degrading enzyme. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9582-9587.	7.1	55
31	Identification of BACE2 as an avid ÃŸ-amyloid-degrading protease. Molecular Neurodegeneration, 2012, 7, 46.	10.8	54
32	Optimization of Peptide Hydroxamate Inhibitors of Insulin-Degrading Enzyme Reveals Marked Substrate-Selectivity. Journal of Medicinal Chemistry, 2013, 56, 2246-2255.	6.4	51
33	Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice. Metabolism: Clinical and Experimental, 2018, 88, 1-11.	3.4	49
34	Cathepsin D regulates cerebral AÎ²42/40 ratios via differential degradation of AÎ²42 and AÎ²40. Alzheimer's Research and Therapy, 2020, 12, 80.	6.2	36
35	Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme. Biomedicines, 2021, 9, 86.	3.2	35
36	The Catalytic Domain of Insulin-degrading Enzyme Forms a Denaturant-resistant Complex with Amyloid Î² Peptide. Journal of Biological Chemistry, 2008, 283, 17039-17048.	3.4	34

#	Article	IF	Citations
37	Targeting Insulin-Degrading Enzyme in Insulin Clearance. International Journal of Molecular Sciences, 2021, 22, 2235.	4.1	31
38	Presenilin-1 Immunoreactivity Is Localized Intracellularly in Alzheimer's Disease Brain, but Not Detected in Amyloid Plaques. Experimental Neurology, 1997, 143, 37-44.	4.1	26
39	Characterization of Insulin Degrading Enzyme and Other Amyloid-Î² Degrading Proteases in Human Serum: A Role in Alzheimer's Disease?. Journal of Alzheimer's Disease, 2012, 29, 329-340.	2.6	26
40	Hepatic insulin-degrading enzyme regulates glucose and insulin homeostasis in diet-induced obese mice. Metabolism: Clinical and Experimental, 2020, 113, 154352.	3.4	25
41	Enzyme target to latch on to. Nature, 2006, 443, 761-762.	27.8	24
42	Proteolytic Degradation of the Amyloid β-Protein: The Forgotten Side of Alzheimers Disease. Current Alzheimer Research, 2006, 3, 431-435.	1.4	24
43	Pancreatic Î²-cell-specific deletion of insulin-degrading enzyme leads to dysregulated insulin secretion and Î²-cell functional immaturity. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E805-E819.	3.5	23
44	Selective Targeting of Extracellular Insulin-Degrading Enzyme by Quasi-Irreversible Thiol-Modifying Inhibitors. ACS Chemical Biology, 2015, 10, 2716-2724.	3.4	22
45	AÎ²-Degrading Proteases: Therapeutic Potential in Alzheimer Disease. CNS Drugs, 2016, 30, 667-675.	5.9	22
46	Regulation of distinct pools of amyloid Î²-protein by multiple cellular proteases. Alzheimer's Research and Therapy, 2013, 5, 37.	6.2	18
47	Peptidic inhibitors of insulin-degrading enzyme with potential for dermatological applications discovered via phage display. PLoS ONE, 2018, 13, e0193101.	2.5	17
48	Herpes Simplex Virus Infections and Alzheimer??s Disease. Drugs and Aging, 1998, 13, 193-198.	2.7	15
49	Insulin-Degrading Enzyme: Paradoxes and Possibilities. Cells, 2021, 10, 2445.	4.1	15
50	Age and Its Association with Low Insulin and High Amyloid-Î² Peptides in Blood. Journal of Alzheimer's Disease, 2015, 49, 129-137.	2.6	12
51	Effects of Fasting and Feeding on Transcriptional and Posttranscriptional Regulation of Insulin-Degrading Enzyme in Mice. Cells, 2021, 10, 2446.	4.1	10
52	Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme. Molecular Neurodegeneration, 2009, 4, 39.	10.8	8
53	Development and Characterization of Quantitative, High-Throughput-Compatible Assays for Proteolytic Degradation of Glucagon. SLAS Discovery, 2018, 23, 1060-1069.	2.7	7
54	AÃŽÂ² degradationÃ¢â‚¬â€the inside story. Frontiers in Aging Neuroscience, 2014, 6, 229.	3.4	5

#	Article	IF	Citations
55	Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition in Vitro. Endocrinology, 2016, 157, 3462-3468.	2.8	5
56	Hydroxypyridinethione Inhibitors of Human Insulinâ€Degrading Enzyme. ChemMedChem, 2021, 16, 1776-1788.	3.2	5
57	Cathepsin D: A Candidate Link between Amyloid Î²-protein and Tauopathy in Alzheimer Disease. Journal of Experimental Neurology, 2021, 2, 10-15.	0.5	4
58	Quantitative, High-Throughput Assays for Proteolytic Degradation of Amylin. Methods and Protocols, 2020, 3, 81.	2.0	3
59	Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation. Diabetologia, 2022, 65, 1375-1389.	6.3	3
60	AÎ² Degradation. , 2007, , 157-178.		1
61	Live discussion: How the other half lives â€“ or the what, how, and where, of the AÎ²PP intracellular domain1. Journal of Alzheimer's Disease, 2004, 6, 193-199.	2.6	0
62	The Blood Glucose-lowering Effect of Racecadotril is not Attributable to Inhibition of Insulin-degrading Enzyme. Hormone and Metabolic Research, 2014, 46, 73-74.	1.5	0